Search Results
Apr 16, 2026, 08:00 ET Piramal Pharma Solutionsと味の素バイオファーマサービス、抗体薬物複合体（ADC）製造支援に向けた戦略的コラボレーションを開始
https://www.ajibio-pharma.com/ja/をご覧ください。Piramal Pharma SolutionsについてPiramal Pharma Solutions（PPS）は、医薬品ライフサイクル全体にわたるエンド・ツー・エンドの開発および製造ソリューションを提供するCDMOです。北米、欧州、アジアに展開するグローバルネットワークを通じて、創薬支援、プロセス・製剤開発、治験薬供給、原薬および製剤の商業生産を行っています。また、高活性原薬（HPAPI）、ADC、無菌製剤、ペプチド医薬品などの専門サービスも提供しています。 詳細は
More news about: Piramal Pharma Solutions
Apr 15, 2026, 08:00 ET Wobble Genomics to Present Novel mRNA Sequencing Research at AACR 2026
approach to sequencing full-length mRNA from blood to support antibody-drug conjugate (ADC) therapy selection in breast cancer. Poster: Sequencing Full-Length mRNA in Whole Blood of Breast Cancer Patients for ADC Therapy SelectionSession: Liquid Biopsies: Circulating Nucleic Acids
More news about: Wobble Genomics
Apr 14, 2026, 20:00 ET 沃特世推出業界首款適用於 UHPLC/UPLC 的寬範圍 MALS 分析系統，助力大分子快速表徵
nm 擴展至 500 nm，能可靠地表徵更大、更複雜的分析物，如蛋白質聚集體、病毒載體、脂質奈米顆粒 (LNP) 和先進材料。由於能測定絕對莫耳質量和尺寸，omniDAWN 分析系統減少了對色譜柱校正標準品的依賴，協助使用者更快獲得結果並進行更可靠的比較，從而簡化生物相似藥研究、抗體偶聯藥物 (ADC) 表徵和病毒載體分析等流程。隨著這些藥物和其他先進療法進入開發後期與品質管制階段，實驗室愈加依賴 UHPLC 和 UPLC 系統來滿足不斷提升的通量與分離度需求。沃特世公司分析科學資深副總裁 Rob Carpio 表示：「針對複雜生物製劑及新型療法的 UHPLC 和 UPLC 分離技術發展迅速，但偵測技術一直未能跟上步伐，如今這個局面被打破。omniDAWN
More news about: Waters Corporation
Apr 14, 2026, 09:08 ET Phrontline Biopharma Presents Preclinical Data for TJ106, a Biparatopic HER2 Dual-Payload ADC, at American Association for Cancer Research Annual Meeting 2026
Data Demonstrate Activity in HER2-Low and ADC-Resistant Tumor Models, Supporting Advancement Toward INDSHANGHAI and SUZHOU, China, April 14, 2026 /PRNewswire/ -- Phrontline Biopharma today announced the presentation
More news about: Phrontline Biopharma
Apr 14, 2026, 08:02 ET GlycoNex Receives PMDA Approval in Japan to Initiate First-in-Human Phase 1 Trial of GNX1021 in Gastrointestinal Cancers
Devices Agency (PMDA) has approved the initiation of a first-in-human (FIH) Phase 1 clinical trial of GNX1021, the company's lead antibody-drug conjugate (ADC) candidate, in patients with advanced gastrointestinal cancers.
More news about: GlycoNex, Inc.
Apr 14, 2026, 08:00 ET Waters Debuts Industry-First Extended-Range MALS Detector for UHPLC/UPLC, Powering Rapid Characterization of Large Molecules
calibration standards and supports faster results and more confident comparisons, streamlining work across biosimilarity studies, antibody-drug conjugate (ADC) characterization, and viral vector analytics. As these modalities and other advanced therapeutics move into late-stage development and quality control,
More news about: Waters Corporation
Apr 14, 2026, 08:00 ET Waters Debuts Industry-First Extended-Range MALS Detector for UHPLC/UPLC, Powering Rapid Characterization of Large Molecules
calibration standards and supports faster results and more confident comparisons, streamlining work across biosimilarity studies, antibody-drug conjugate (ADC) characterization, and viral vector analytics. As these modalities and other advanced therapeutics move into late-stage development and quality control,
More news about: Waters Corporation
Apr 14, 2026, 06:00 ET Adcendo ApS Completes $75 Million Series C Financing to Continue Advancing First- and Best-in-class Clinical ADC Pipeline
will be used to support Adcendo through multiple upcoming key clinical milestones from the Company's first- and best-in-class ADC pipeline, including the ADCE-T02 (Tissue Factor ADC) Phase I Tiffany-01 Cohort expansion study in multiple high unmet need tumor indications, the ADCE-D01 (uPARAP) ADCElerate1
More news about: Adcendo
Apr 14, 2026, 06:00 ET Adcendo ApS Completes $75 Million Series C Financing to Continue Advancing First- and Best-in-class Clinical ADC Pipeline
will be used to support Adcendo through multiple upcoming key clinical milestones from the Company's first- and best-in-class ADC pipeline, including the ADCE-T02 (Tissue Factor ADC) Phase I Tiffany-01 Cohort expansion study in multiple high unmet need tumor indications, the ADCE-D01 (uPARAP) ADCElerate1
More news about: Adcendo
Apr 13, 2026, 20:00 ET Kelun-Biotech Announces Results from the SKB264-II-06/MK-2870-002 Study of Sacituzumab Tirumotecan (Sac-TMT) in Gynecologic Oncology Presented at 2026 SGO
in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please
More news about: Kelun-Biotech
Apr 12, 2026, 07:15 ET AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026
enrollment of participants most likely to benefit from this FRα‑targeted ADC approach.About ELAHERE®ELAHERE® (mirvetuximab soravtansine-gynx) is a first-in-class antibody-drug conjugate (ADC) comprising a folate receptor alpha-binding antibody, cleavable linker
More news about: AbbVie
Apr 10, 2026, 07:25 ET DualityBio gibt Annahme des Zulassungsantrags für Trastuzumab Pamirtecan zur Behandlung von nicht resezierbarem oder metastasiertem HER2-positivem Brustkrebs bei erwachsenen Patienten durch die chinesische NMPA bekannt
und führenden Biotech-Innovatoren aufgebaut. Als global führendes Unternehmen im ADC-Bereich entwickelt DualityBio neuartige ADCs, darunter bispezifische ADC-Kandidaten, ADC-Kandidaten mit neuartigen Nutzlasten sowie ADC-Kandidaten für Autoimmunerkrankungen.Weitere Informationen finden Sie auf
More news about: DualityBio
Apr 10, 2026, 07:23 ET DualityBio annonce l'acceptation par la NMPA chinoise de la demande d'autorisation de mise sur le marché du trastuzumab pamirtecan pour le traitement du cancer du sein HER2 positif non résécable ou métastatique chez l'adulte
biotechnologiques de premier plan. En tant qu'acteur majeur dans le domaine des ADC, DualityBio développe de nouveaux ADC, notamment des candidates ADC bispécifiques, des candidates ADC à charge utile innovante et des candidates ADC auto-immuns.Pour plus d'informations, veuillez consulter le site
More news about: DualityBio
Apr 10, 2026, 07:00 ET Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026
biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today presented three posters from a real-world analysis supporting the therapeutic potential of targeting mucin 16 (MUC16) with a next-generation ADC for the treatment of ovarian and endometrial cancers at the Society
More news about: Whitehawk Therapeutics, Inc.
Apr 09, 2026, 12:55 ET DualityBio anuncia la aceptación de NMPA de China de su solicitud de licencia para productos biológicos
candidatos a ADC en fase clínica.Además, DualityBio ha establecido colaboraciones estratégicas con multinacionales globales e innovadores biotecnológicos líderes. Como potencia mundial en el campo de los ADC, DualityBio está desarrollando nuevos ADC, incluyendo candidatos a ADC biespecíficos,
More news about: DualityBio
Apr 09, 2026, 12:28 ET Aqaba to Host Landmark Global Marine Sports and Diving Event with Participation from 25 Countries in September 2026
future of the sector.The exhibition is organized by Arabia First for Conferences and Exhibitions, hosted by the Aqaba Development Corporation (ADC), and held in strategic partnership with Fira Barcelona, one of the world's leading exhibition organizers.The event represents a strategic step
More news about: Aqaba Blue Ocean Future in Action
Apr 09, 2026, 08:16 ET DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast Cancer
strategic collaborations with global MNCs and leading biotech innovators. As a global ADC powerhouse, DualityBio is developing novel ADCs, including bispecific ADC candidates, novel-payload ADC candidates, and autoimmune ADC candidates.For more information, please visit
More news about: DualityBio
Apr 09, 2026, 07:55 ET DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast Cancer
strategic collaborations with global MNCs and leading biotech innovators. As a global ADC powerhouse, DualityBio is developing novel ADCs, including bispecific ADC candidates, novel-payload ADC candidates, and autoimmune ADC candidates.For more information, please visit
More news about: DualityBio
Apr 09, 2026, 06:20 ET Kelun-Biotech Approved by HKEX to Remove "B" Marker from Stock Code, Representing a New Stage of Development
in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please
More news about: Kelun-Biotech
Apr 08, 2026, 09:00 ET Altruist Biologics' Hangzhou Facility Secures First Commercial Manufacturing License
bioreactors, the first and largest of their kind in China. The site will hold a total capacity of 172,000 liters upon completion. It also offers a standalone ADC and AXC bioconjugation facility to support the manufacture of various bioconjugates, including high potency ADCs for clinical and commercial supply in
More news about: Altruist Biologics
Apr 08, 2026, 09:00 ET Altruist Biologics' Hangzhou Facility Secures First Commercial Manufacturing License
bioreactors, the first and largest of their kind in China. The site will hold a total capacity of 172,000 liters upon completion. It also offers a standalone ADC and AXC bioconjugation facility to support the manufacture of various bioconjugates, including high potency ADCs for clinical and commercial supply in
More news about: Altruist Biologics
Apr 07, 2026, 10:30 ET EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion
TUB-040, a NaPi2b-directed topoisomerase-I inhibitor (TOPO1i) ADC, is currently in Phase 1b/2 development for platinum-resistant ovarian cancer and non-small cell lung cancer (NSCLC). Gilead will also acquire TUB-030, a 5T4 targeted ADC, which has demonstrated promising initial clinical data across various
More news about: EQT
Apr 07, 2026, 10:27 ET EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion
TUB-040, a NaPi2b-directed topoisomerase-I inhibitor (TOPO1i) ADC, is currently in Phase 1b/2 development for platinum-resistant ovarian cancer and non-small cell lung cancer (NSCLC). Gilead will also acquire TUB-030, a 5T4 targeted ADC, which has demonstrated promising initial clinical data across various
More news about: EQT
Apr 06, 2026, 23:28 ET Akeso Presents Updated Data on Cadonilimab Combination Therapy in PD-(L)1 Inhibitor-Resistant Advanced NSCLC at ELCC 2026
established a robust R&D innovation ecosystem centered on its Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.
More news about: Akeso, Inc.
Apr 06, 2026, 10:00 ET K-679: A Novel Antibody Drug-loaded Unimicelle Conjugate Demonstrates Tumor-Selective Pharmacokinetics, Extensive Intratumoral Distribution and Superior Efficacy in Non-Clinical Animal Models
Meeting 2026 | Meetings | AACRAbout K-679K-679 is an Antibody Drug-loaded Unimicelle Conjugate (ADUC), a novel type of ADC using Kowa's proprietary micelle technology, currently in nonclinical development. The conjugate combines an anti-EGFR antibody with drug (DM1)-loaded
More news about: Kowa Company Ltd.